by Stacey Johnson | Aug 29, 2017
The crux of Right to Try legislation, enacted by 37 U.S. states so far, is the premise that terminally ill patients should have access to experimental therapies, even if they haven’t been approved by the Food and Drug Administration yet. It sounds straight-forward...
by David Kent | Aug 29, 2017
As with all of my posts that relate to anything that might end up being a medical treatment, it is important to be very clear that I am a scientist and not a physician. My comments are my own opinion and based on my experience as a stem cell biologist over the last...
by Stacey Johnson | Aug 25, 2017
On Tuesday, August 29, Signals is hosting a blog carnival on the topic Right to Try. Before you read the perspectives of the contributing bloggers, here’s what President Trump thinks about the legislation and the Goldwater Institute’s reaction. It’s the Institute that...
by Stacey Johnson | Aug 9, 2017
Although new to the field of science communication, Nathan Holwell has been involved in a variety of research during his undergraduate career and now in his graduate career. He has done research in drug delivery, gene delivery, biomaterials and diagnostic devices. His...
Comments